11. 重症筋無力症 Myasthenia gravis Clinical trials / Disease details

臨床試験数 : 315 / 薬物数 : 232 - (DrugBank : 77) / 標的遺伝子数 : 46 - 標的パスウェイ数 : 126

11 trials found

diseases per page:

Showing 1 to 10 of 11 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2020-000949-14-DE (EUCTR)	30/07/2021	08/12/2020	Inebilizumab efficacy and safety in adults with myasthenia gravis	A RANDOMIZED, DOUBLE-BLIND, MULTICENTER,PLACEBO-CONTROLLED PHASE 3 STUDY WITHOPEN-LABEL PERIOD TO EV ...	Myasthenia Gravis which is either due to acetylcholinereceptor antibodies (AChR) or muscle specific ...	Trade Name: Uplizna Product Name: Inebilizumab INN or Proposed INN: INEBILIZUMAB Other descriptive name ...	Viela Bio, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	270	Phase 3	United States;Belarus;Taiwan;Spain;Ukraine;Turkey;Israel;Russian Federation;Italy;India;France;Canad ...
2	EUCTR2020-000949-14-DK (EUCTR)	24/02/2021	24/11/2020	Inebilizumab efficacy and safety in adults with myasthenia gravis	A RANDOMIZED, DOUBLE-BLIND, MULTICENTER,PLACEBO-CONTROLLED PHASE 3 STUDY WITHOPEN-LABEL PERIOD TO EV ...	Myasthenia Gravis which is either due to acetylcholinereceptor antibodies (AChR) or muscle specific ...	Trade Name: Uplizna Product Name: Inebilizumab INN or Proposed INN: INEBILIZUMAB Other descriptive name ...	Viela Bio, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	270	Phase 3	United States;Belarus;Taiwan;Spain;Ukraine;Turkey;Israel;Russian Federation;Italy;India;France;Canad ...
3	NCT05091177 (ClinicalTrials.gov)	January 1, 2021	9/10/2021	Study on Correlation Between Cytomegalovirus and Ocular Myasthenia Gravis	Study on Correlation Between Cytomegalovirus and Ocular Myasthenia Gravis	Ocular Myasthenia Gravis;Cytomegalovirus Infections	Diagnostic Test: Serum acetylcholinereceptor antibody, erythrocyte deposition rate, hypersensitive C ...	XiaoYong Liu	NULL	Recruiting	18 Years	50 Years	All	125		China
4	EUCTR2020-000949-14-FR (EUCTR)	16/11/2020	08/10/2020	Inebilizumab efficacy and safety in adults with myasthenia gravis	A RANDOMIZED, DOUBLE-BLIND, MULTICENTER,PLACEBO-CONTROLLED PHASE 3 STUDY WITHOPEN-LABEL PERIOD TO EV ...	Myasthenia Gravis which is either due to acetylcholinereceptor antibodies (AChR) or muscle specific ...	Product Name: Inebilizumab INN or Proposed INN: INEBILIZUMAB Other descriptive name: CD19-directed hum ...	Viela Bio, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	252	Phase 3	Ukraine;United States;Belarus;Finland;Spain;Guatemala;Turkey;Russian Federation;Israel;Italy;India;F ...
5	NCT03579966 (ClinicalTrials.gov)	July 1, 2018	5/6/2018	Long Term Safety Study of Amifampridine Phosphate in MuSK-MG (Muscle Specific Tyrosine Kinase Myasth ...	Long Term Safety Study of Amifampridine Phosphate in Patients With MuSK Antibody Positive and AChR ( ...	Myasthenia Gravis, MuSK	Drug: Amifampridine Phosphate	Catalyst Pharmaceuticals, Inc.	NULL	Active, not recruiting	18 Years	N/A	All	70	Phase 3	United States
6	EUCTR2017-000323-27-NL (EUCTR)	03/08/2017	18/04/2017	A study to evaluate the efficacy of CV-MG01 (Myasterix), a therapy for Myasthenia gravis	A Multi-center, Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the E ...	Myasthenia Gravis (MG) is a chronic neuromuscular disorder characterized by weakness and fatigabilit ...	Product Name: CV-MG01 INN or Proposed INN: Not applicable Other descriptive name: T-peptide-CRM197 con ...	CuraVac Europe SA	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	66	Phase 2;Phase 3	Belgium;Netherlands
7	EUCTR2017-000323-27-BE (EUCTR)	19/06/2017	13/04/2017	A study to evaluate the efficacy of CV-MG01 (Myasterix) in Myasthenia Gravis	A Multi-center, Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the E ...	Myasthenia Gravis (MG) is a chronic neuromuscular disorder characterized by weakness and fatigabilit ...	Product Name: CV-MG01 INN or Proposed INN: Not applicable Other descriptive name: T-peptide-CRM197 con ...	CuraVac Europe SA	NULL	Not Recruiting			Female: yes Male: yes	66	Phase 2;Phase 3	Belgium;Netherlands
8	NCT02609022 (ClinicalTrials.gov)	March 2016	13/11/2015	Safety, Tolerability and Immunogenic Response of CV-MG01 in Patients With Myasthenia Gravis	A First-in-human and Proof-of-concept Study to Assess the Safety, Tolerability and Immunogenic Respo ...	Myasthenia Gravis	Biological: CV-MG01;Biological: Placebo	CuraVac	Aepodia;University Hospital, Antwerp;Leiden University Medical Center	Completed	18 Years	64 Years	All	24	Phase 1/Phase 2	Belgium
9	EUCTR2015-000097-35-DK (EUCTR)	03/09/2015	16/06/2015	Safety, tolerability and efficacy of CFZ533 in the treatment of moderate to severe myasthenia gravis ...	A multi-center, randomized, double-blind, placebo-controlled, parallel group study to preliminarily ...	Acquired myasthenia gravis (MG) is an autoimmune disease that leads to fluctuating muscle weakness a ...	Product Code: CFZ533 Other descriptive name: CFZ533	Novartis Pharma Services AG	NULL	Not Recruiting			Female: yes Male: yes	44	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - ( ...	Germany;Russian Federation;Denmark;Canada;Taiwan
10	EUCTR2015-000097-35-DE (EUCTR)	02/09/2015	05/06/2015	Safety, tolerability and efficacy of CFZ533 in the treatment of moderate to severe myasthenia gravis ...	A multi-center, randomized, double-blind, placebo-controlled, parallel group study to preliminarily ...	Acquired myasthenia gravis (MG) is an autoimmune disease that leads to fluctuating muscle weakness a ...	Product Code: CFZ533 Other descriptive name: CFZ533	Novartis Pharma Services AG	NULL	Not Recruiting			Female: yes Male: yes	44	Phase 2	Taiwan;Canada;Denmark;Russian Federation;Germany

First Previous1 2Next Last